Endocrine Abstracts

Background: National Institute for Health and Clinical Excellence (NICE) guidelines advise that GDM be diagnosed using a 2-hr 75 g oral glucose tolerance test (OGTT). However there is lack of consensus on the optimal postpartum surveillance. Current postpartum screening guidance suggests a single fasting plasma glucose (FPG) at 6-weeks with annual testing thereafter. As women with GDM are often from mixed ethnic groups and frequently have postprandial hyperglycaemia, ...

Background: Radioiodine (131I) therapy is performed in patients with differentiated thyroid cancer (DTC), either for thyroid remnant ablation or treating distant metastasis. Although 131I therapy is generally considered safe, a genotoxic damage has been demonstrated both in vivo and in vitro.Aim: To evaluate the possible effect of Ginkgo biloba extract (EGb 761) supplementation on the time-course (up to 1...

The long-term risk of carcinogenic and genetic damage following the treatment with 131I for differentiated thyroid cancer (DTC) is quite low. The hypothyroid status (HS), at the time of 131I administration, decreases the renal clearance of 131I and increases the whole-body, blood and bone marrow irradiation, unlike the euthyroid status (ES). Chromosome aberrations (CA) in peripheral lymphocytes reflect blood cells exposure to irradiation. This ...

Background: Graves’ disease (GD) is an autoimmune disorder of thyroid gland and is the first cause of hyperthyroidism. Radioactive iodine (RAI) therapy is the most used second- line treatment after failure of anti-thyroid drugs. The optimal RAI’s activity to be administered may be predetermined or calculated. Whether the latter is better is still a matter of debate.Aim: To compare the risk of persistent hyperthyroidism in GD patients treated wi...